Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a

Multiple Sclerosis Journal

Volumn 20, Issue 4, 2014, Pages 445-450

  Hedström, Anna Karin ^a   Ryner, Malin ^b   Fink, Katarina ^b   Fogdell Hahn, Anna ^b   Alfredsson, Lars ^a   Olsson, Tomas ^b   Hillert, Jan ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Beta interferon; immunology; lungs; multiple sclerosis; neutralizing antibody; risk; smoking; snuff; tobacco use

Indexed keywords

BETA1A INTERFERON; INTERFERON ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SMOKELESS TOBACCO; SMOKING; SWEDEN; CASE CONTROL STUDY; IMMUNOREACTIVITY; LUNG; RISK FACTOR; SMOKING HABIT; SWEDISH CITIZEN;

BETA-INTERFERON; IMMUNOLOGY; LUNGS; MULTIPLE SCLEROSIS; NEUTRALIZING ANTIBODY; RISK; SMOKING; SNUFF; TOBACCO USE;

ADULT; ANTIBODIES, NEUTRALIZING; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; REGISTRIES; RISK FACTORS; SMOKING;

EID: 84896127708     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513498635     Document Type: Article

References (23)

1. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003 ; 362: 1184-1191
2. Hesse D, Sellebjerg F, Sorensen PS.. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009 ; 73: 372-377
3. Bertolotto A, Deisenhammer F, Gallo P, et al. Immunogenicity of interferon beta: Differences among products. J Neurol. 2004 ; 251: II15-24
4. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet. 2008 ; 83: 219-227
5. Sena A, Bendtzen K, Cascais MJ, et al. Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralizing antibodies to interferon-beta. J Neurol. 2010 ; 257: 1703-1707
6. Sopori M.. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002 ; 2: 372-377
7. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008 ; 67: 1488-1492
8. Cloos PA, Christgau S. Post-translational modifications of proteins: Implications for aging, antigen recognition and autoimmunity. Biogerontology. 2004 ; 5: 139-158
9. Doyle HA, Mamula MJ. Posttranslational protein modifications: New flavors in the menu of autoantigens. Curr Opin Rheumatol. 2002 ; 14: 244-249
10. Hedström AK, Bäärnhielm M, Olsson T, et al. Tobacco smoking, but not Swedish snuff usage, increases the risk of multiple sclerosis. Neurology. 2009 ; 73: 696-701
11. Hedström AK, Åkerstedt T, Hillert J, et al. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol. 2011 ; 67: 110-117
12. Sørensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005 ; 12: 817-827
13. Sominanda A, Rot U, Suoniemi M, et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler. 2007 ; 13: 208-214
14. Bertolotto A, Sala A, Caldano M, et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Meth. 2007 ; 321: 19-31
15. Kawade Y. Quantitation of neutralization of interferon by antibody. Meth Enzymol. 1986 ; 119: 558-573
16. Gneiss C, Tripp P, Reichartseder F, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler. 2006 ; 12: 731-737
17. Herndon RM, Rudick RA, Munschauer FE, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler. 2005 ; 11: 409-419
18. Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler. 2012 ; 18: 610-615
19. Shan M, Cheng HF, Song LZ, et al. Lung myeloid dendritic cells coordinately induce Th1 and Th17 responses in human emphysema. Sci Transl Med. 2009 ; 1: 4ra10
20. Hedström AK, Sundqvist E, Bäärnhielm M. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain. 2011 ; 134: 653-664
21. Mahdi H, Fisher BA, Kallberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 2009 ; 41: 1319-1324
22. Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the central nervous system. Nature. 2012 ; 488: 675-679
23. Wingerchuk DM. Smoking: Effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012 ; 5: 13-22